Acadian Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Acadian Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,025	Closed	-$52K	–	2304
2021 Q1	$52K	Buy	2,025 +997	+97%	+$25.5K	﹤0.01%	1816
2020 Q4	$23K	Buy	+1,028	New	+$22.6K	﹤0.01%	2131
2020 Q1	–	Sell	-4,334	Closed	-$95K	–	2003
2019 Q4	$95K	Buy	+4,334	New	+$87.2K	﹤0.01%	1476
2018 Q2	–	Sell	-23,566	Closed	-$225K	–	1906
2018 Q1	$225K	Buy	+23,566	New	+$254K	﹤0.01%	1033
2017 Q2	–	Sell	-325	Closed	-$1K	–	1666
2017 Q1	$1K	Buy	+325	New	+$915	﹤0.01%	1531
2015 Q3	–	Sell	-964	Closed	-$13K	–	1483
2015 Q2	$13K	Buy	+964	New	+$17.7K	﹤0.01%	1133

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Acadian Asset Management's DRNA Position: Q2 2021 in Review

Acadian Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2021, closing a stake of 2,025 shares — an estimated $52K sold.

Acadian Asset Management first reported a position in DRNA in Q2 2015 and held it in 6 quarters. The position peaked at $225K in Q1 2018. 203 funds tracked by Wall St. Rank hold DRNA as of Q2 2021.

Acadian Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Acadian Asset Management sold 2,025 Dicerna Pharmaceuticals, Inc. shares in Q2 2021, an estimated $52K.
Acadian Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2015 and held it in 6 quarters.
Acadian Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $225K in Q1 2018.
203 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2021.

Based on Acadian Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.